This podcast, hosted by renowned hepatologist Dr. Robert Gish, will delve into various topics related to liver disease. These will include hepatitis, cholestatic liver disease, diagnostics, testing methods, treatment options, stigma and other related topics. If you are a gastroenterologist, hepatologist, liver disease fellow or a patient with liver disease, this podcast is for you!
Bepirovirsen (BEPI): A New Hope for Functional Cure in Hepatitis B
Welcome to a new season of podcasts from Dr. Robert Gish!
In this latest podcast, Dr. Robert Gish discusses bepirovirsen (BEPI), an antisense oligonucleotide in development for the treatment of chronic hepatitis B. He explains how BEPI targets hepatitis B viral RNA and why this emerging therapy could represent an important step beyond long-term nucleos(t)ide therapy.
Dr. Gish reviews key results from the B-Well 1 and B-Well 2 Phase 3 studies, including functional cure rates and the potential for finite therapy and treatment discontinuation in selected patients. He also highlights the importance of quantitative hepatitis B surface antigen (qHBsAg) in identifying patients who may benefit.
With new data showing substantially higher functional cure rates than those typically achieved with nucleos(t)ide analogues, BEPI could open new doors and bring new hope to the treatment of chronic hepatitis B.
Please feel free to send any questions or feedback to Dr. Gish via email rgish@robertgish.com or via his website www.robertgish.com
Thank you for listening!
14 Mar 2025
When Do I Use Resmetirom for Nonalcoholic Steatohepatitis (NASH)
With the recent renaming of NASH to MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) and the evolving landscape of treatment, when is the right time to use resmetirom? In this episode, we explore how this thyroid hormone receptor-β agonist is changing the management of MASLD, particularly in patients with significant fibrosis. We also break down non-invasive testing methods—for instance, elastography, CAP scores, (FibroScan), ELF score, and FIB4—to help stage patients and guide treatment decisions.
Tune in as we discuss the science, clinical guidelines, and real-world considerations for incorporating resmetirom into patient care!
Please feel free to send any questions or feedback to Dr. Gish via email rgish@robertgish.com or via his website www.robertgish.com
Thank you for listening!
27 Feb 2025
Primary Biliary Cholangitis & Second Line Therapy
In this episode, Dr. Robert Gish, a leading expert in liver diseases, dives deep into second-line therapies for Primary Biliary Cholangitis (PBC), a chronic autoimmune liver disease. Dr. Gish explores key treatment options, including Ursodeoxycholic Acid (UDCA/"Urso" first-line), obeticholic acid (OCA/Ocaliva), elafibranor, and eeladelpar, discussing their mechanisms, benefits, and how they can be used to manage PBC. He also addresses the persistent challenge of managing pruritus (itch), a common symptom for patients. With a variety of treatment options available, Dr. Gish emphasizes that no PBC patient, in our ideal patient management world, should be progressing to the point of needing a liver transplant, and discusses how careful management can prevent disease progression. This episode provides valuable insights for both patients and healthcare providers looking to improve outcomes in PBC treatment.
Please feel free to send any questions or feedback to Dr. Gish via email rgish@robertgish.com or via his website www.robertgish.com
Thank you for listening!
13 Feb 2025
Exploring HepQuant DuO - Liver Function Test
Join Dr. Robert Gish, a leading expert in liver health and diagnostics, in this deep dive into HepQuant DuO, a groundbreaking tool for assessing liver function. Dr. Gish will discuss how HepQuant DuO works, its significance in clinical practice, and the impact it has on patient care. Whether you’re a healthcare professional, a student, or simply curious about liver health, this podcast promises to enhance your understanding of modern diagnostics and the future of liver disease management. Tune in to discover how HepQuant DuO is revolutionizing the way we approach liver assessment!
As always, you can send questions or feedback to Dr. Gish via email rgish@robertgish.com or via his website www.robertgish.com
Thank you for listening!
16 Jan 2025
When and How to Use the Direct Bilirubin
In this episode, Dr. Robert Gish explores liver function tests (bilirubin, albumin and INR), with a focus on total and more importantly on direct bilirubin. He explains how these tests help doctors assess liver health and clarifies the difference between liver function tests and liver enzyme tests.
Many providers and patients are very confused when we use the term “liver function test” in our conversations. It is important to differentiate liver enzymes from function specifically in our dialogue with providers and patients to provide reassurance about liver health status. Bilirubin is the best liver function test, and direct bilirubin is the most useful inside measuring a total bilirubin. Albumin and INR are also helpful function tests. AST, ALT alkaline phosphate and GGT are not liver function tests. These are liver enzymes, and we should only use that term.
Dr. Gish also discusses Gilbert Syndrome (he was British not French), a common condition that can affect bilirubin levels. Tune in for expert insights on how to interpret direct bilirubin lab results and gain a better understanding of what your liver function tests can reveal. Whether you're a patient looking to make sense of your results or a healthcare professional seeking clarity, this episode offers valuable information.
Be sure to send any questions to Dr. Gish via email rgish@robertgish.com or via his website www.robertgish.com. Thank you for listening!
2 Jan 2025
Hepatitis Delta
In this enlightening episode, Dr. Robert Gish, a renowned expert in hepatology, explores the complexities of Hepatitis Delta (HDV), a deadly form of viral hepatitis. Dr. Gish emphasizes why all Hepatitis B (HBV) patients must be tested for HDV total antibodies, and if positive, further tested for HDV RNA quantification. He explains the significant risks HDV poses to liver health, its interaction with HBV, and the urgent need for proper diagnosis and management.
With new treatments on the horizon, Dr. Gish highlights the latest advancements in therapy, offering hope for more effective care. Whether you're a healthcare professional or someone interested in learning more about Hepatitis Delta, this episode provides crucial insights into testing, treatment options, and the future of HDV care.
Tune in for valuable info on how to navigate the challenges of Hepatitis Delta and the promising new approaches to treatment.
Be sure to send any questions to Dr. Gish via email rgish@robertgish.com or via his website www.robertgish.com. Thank you for listening!
21 Dec 2024
Statins in Chronic Liver Disease
Dr. Robert Gish explores the risks and benefits of statins in chronic liver disease, dispelling myths and providing evidence-based insights for effective patient care.
5 Dec 2024
Cuvrior: A New Treatment for Wilson Disease
Dr. Robert Gish discusses the revolutionary Cuvrior treatment for Wilson disease, offering a safer, more convenient, and potentially more affordable option for patients.
22 Nov 2024
How To Use Noninvasive Testing (NITs) in Your Practice Today
Dr. Robert Gish explores the critical role of Noninvasive Testing in diagnosing and staging liver conditions, empowering healthcare professionals to provide optimal care for liver patients.
7 Nov 2024
When to Order a Gamma-Glutamyl Transferase (GGT)
In this episode, Dr. Robert Gish, a renowned expert in hepatology, examines the critical role of the Gamma-Glutamyl Transferase (GGT) test in assessing liver health. Dr. Gish explains why GGT is an essential part of the liver enzyme panel and how it provides vital insights into a patient's inflammatory status, especially when alkaline phosphatase (ALP) alone may not be sufficient due to its limited sensitivity and specificity.
Tips for Providers:
When ordering a liver enzyme panel, remember the "4 pillars" for a comprehensive evaluation of a patient's liver health, and always include GGT.
Very high GGT values, when used in conjunction with PEth (Phosphatidylethanol) testing, can be an effective tool in identifying alcohol use disorder and alcohol-related liver disease.
Disparate GGT and ALP levels can identify genetic diseases such as PFIC and other cholestatic variants.
Keep in mind that high alkaline phosphatase levels can sometimes be misleading, as they may be caused by conditions like hyperparathyroidism or vitamin D deficiency, rather than liver disease.
Join Dr. Gish as he shares practical tips, clinical insights, and expert advice for better interpreting these vital lab tests to improve patient outcomes. Whether you're a seasoned clinician or just starting out, this episode is packed with valuable takeaways for anyone involved in liver care.
Please send any questions to Dr. Gish via email rgish@robertgish.com or via his website www.robertgish.com. Thanks for listening!
24 Oct 2024
Thromboelastography (TEG)
In this latest episode of "Everything Liver," Dr. Robert Gish delves into the intricacies of thromboelastography (TEG) and its pivotal role in patient care. Join Dr. Gish as he breaks down how to interpret TEG test results, emphasizing its importance in the clinical setting. With an engaging analogy, he compares TEG to the cutting-edge F-35 jet, showcasing its precision and versatility, while likening the traditional INR test to a Model T—valuable but limited in scope. Discover why understanding TEG is essential for optimizing treatment plans and improving patient outcomes in liver health. Tune in for insights that could revolutionize your approach to coagulation testing!
Be sure to send any questions to Dr. Gish via email rgish@robertgish.com or via his website www.robertgish.com. Thank you for listening!
10 Oct 2024
Hepatitis B Virus - Treat All Approach
Join Dr. Gish, a leading expert in infectious diseases, as he delves into the complexities of Hepatitis B Virus (HBV) and the innovative "Treat All" approach. In this episode, Dr. Gish explores the 10 important reasons why we propose to treat all patient with HBV who are HBV DNA+
HBV DNA+ correlates with risk: risk of HCC, cirrhosis, liver transplant and death
Treatment decreases risk: 70% less HCC and 90% decrease in cirrhosis and liver transplant
Decrease Risk of Transmission U=U
Treatment to prevent infection
Reduce Stigma
Improve QOL
Reduce HBV related extrahepatic disease
Decrease other HBV related cancers (bile duct cancer is an example)
Reduce Discrimination
Partner with Patients who request treatment
Listeners will gain insights into the importance of early diagnosis, the benefits of universal treatment, and the impact of Hepatitis B on global health. Whether you're a healthcare professional, a patient, or simply curious about liver health, this podcast offers valuable information and expert perspectives to empower and inform. Tune in to learn how we can work together to eliminate Hepatitis B!
As always, please share your comments or questions with Dr. Gish via email rgish@robertgish.com (mailto:rgish@robertgish.com) or via his website www.robertgish.com
Thank you for listening!
26 Sept 2024
When and how do you use phosphatidylethanol (PETH) testing in your clinical practice
In this episode, Dr. Gish delves into the crucial role of phosphatidylethanol (PETH) testing in detecting alcohol use among patients in your general clinic, for those who have undergone liver transplants or individuals being evaluated for liver transplantation. Understanding alcohol consumption quantity is vital for patient safety and optimal outcomes, and PETH serves as an invaluable tool in this process.
Join us as we discuss: What PETH is and how it works, its significance in general practice and for liver transplant evaluations, and best practices for interpreting results.
Please share any comments or questions on social media, message Dr. Gish via his website www.robertgish.com or email at rgish@robertgish.com (mailto:rgish@robertgish.com)
Thanks for tuning in!
12 Sept 2024
Progressive familial intrahepatic cholestasis (PFIC) and genetic testing for cholestatic liver disease
Welcome back to Dr. Robert Gish's podcast series! In this episode, he's diving deep into the world of Cholestasis with a focus on Progressive Familial Intrahepatic Cholestasis, or PFIC. Dr. Gish will unravel the complexities of this rare and challenging liver condition, exploring its genetic underpinnings and the latest advancements in genetic testing for many other forms of cholestasis as well.
PFIC is a group of genetic disorders that impair bile flow, leading to progressive liver damage. Understanding its genetic basis is crucial for accurate diagnosis, prognosis, and treatment planning. There are 77 mutations that can now be detected using the Prevention Genetics Panel that have or may have a link to various forms of cholestasis. Dr. Gish will shed light on the latest developments in genetic testing for cholestatic liver diseases, discussing how these advancements can improve patient outcomes and tailor personalized treatment strategies.
Whether you're a healthcare professional, a patient, or simply curious about liver health, this episode promises valuable insights and perspectives. Don’t miss it as we continue our journey into the cutting-edge world of liver disease research and treatment with one of the leading experts in the field.
Please let us know your thoughts - you can send Dr. Gish a message through his website www.robertgish.com, on Facebook or via email rgish@robertgish.com.
29 Aug 2024
HCC Screening And Surveillance Risk Biomarkers
In his first podcast, Dr. Robert Gish discusses Hepatocellular carcinoma (HCC) Screening And Surveillance Risk Biomarkers, how to use and what to order.
Learn more about Dr. Gish at his website www.robertgish.com and send any questions or feedback to him at rgish@robertgish.com
Dr. Gish will be releasing new podcasts every other week so tune in for more.
Thank you for listening!
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Apple Podcasts (US)
5.0 / 5
1 ratings
Spotify
5.0 / 5
2 ratings
Podcast Authority Score: 36 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
Quality
59
Social presence
0
YouTube
0
Engagement
32
Host of Liver Disease - Testing & Treatment?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
